Anemia in cancer: Therapeutic implications and interventions

Cancer Nursing

Volumn 26, Issue 2, 2003, Pages 119-130

  Gillespie, Theresa W ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Anemia; Cancer; Outcomes; Quality of life; Symptom management

Indexed keywords

IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW TOXICITY; CANCER; CANCER CELL; CANCER THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISTRESS SYNDROME; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; HEMOGLOBIN DETERMINATION; HUMAN; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SUPPLEMENTATION; SURVIVAL; SYMPTOM; TUMOR;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037380341     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200304000-00005     Document Type: Article

References (61)

1. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:424-867.
2. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998;18:156-169.
3. Tuman KJ. Tissue oxygenation delivery. Anesthesiol Clin North Am. 1990;8:451-469.
4. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994;21:38.
5. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26(4):303-311.
6. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant. 1999;14(Suppl 2):85-92.
7. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol. 1998;25(3 Suppl 7):27-34.
8. Ozguroglu M, Arun B, Demir G, et al. Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000;17:29-34.
9. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
10. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol. 1994;68:215-223.
11. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol. 1998;25(3 Suppl 7):26.
12. Nowrousian MR, Kasper C, Oberhoff C, et al. Pathophysiology of cancer-related anemia. In: Smith JF, Boogaerts MA, Ehmer B, eds. rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker; 1997:13-34.
13. Thatcher N. Controlled study of the efficacy and safety of recombinant human erythropoietin in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy. Ann Oncol. 1994;5:89.
14. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist. 1996;1:140-50.
15. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
16. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
17. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACTAn) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13-19.
18. Skillings JR, Rogers-Melamed I, Nabholtz JM. An epidemiological review of anaemia in cancer chemotherapy in Canada. Presented at the European Conference on Clinical Oncology and Cancer Nursing/European Society of Therapeutic Radiology and Oncology. Paris, France; 1995:183.
19. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 2000;5(Suppl 2):17.
20. Barrett-Lee PJ, Bailey NP, O'Brien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82(1):93-97.
21. Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol. 1999;10(Suppl 5):S91-S94.
22. Sabbatini F. Treating cancer symptoms improves quality of life: Part 1. treatment of anaemia and fatigue. Int J Pharmacol. 2000;14:88-91.
23. Kelleher DK, Mattheinsen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996;56:4728-4734.
24. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 2000;5(Suppl 2):13-18.
25. Obermair A, Petru E, Windbichler G, et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep. 2000;7:639-644.
26. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 8527. Int J Radiat Oncol Biol Phys. 1998;42:1069-1075.
27. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol. 1998;174(Suppl 4):24-30.
28. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP. Anemia, hypoxia, and transfusion in patients with cervix cancer: a review. Radiother Oncol. 2000;57:13-19.
29. Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
30. Dunst J, Pigorsch S, Hansgen G, et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol. 1999;175:93-96.
31. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536.
32. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol. 1997;34(3 Suppl 2):20-26.
33. Daneryd P, Svanberg E, Korner U, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res. 1998;58:5374-5379.
34. Curt GA. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist. 2000;5(Suppl 2):9-12.
35. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34(3 Suppl 2):4-12.
36. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
37. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response of tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
38. Gabrilove JL, Cleeland C, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
39. Adamson JW. Epoetin alfa: into the new millennium. Semin Oncol. 1998;25(3 Suppl 7):76-79.
40. Feelders RA, Vreugdenhil G, Eggermont AM, et al. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production, and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 1998;28:520-527.
41. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology. 1999;13:461-473.
42. Henry D. Changing patterns of care in the management of anemia. Semin Oncol. 1992;19:3-7.
43. Blumberg N, Heal J. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med 1996;101:299-308.
44. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol. 1997;34(3 Suppl 2):34-40.
45. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs. 1989;38:863-899.
46. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(Suppl 2):S2-S8.
47. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol. 1998;25(3 Suppl 7):23-36.
48. Marsh WA, Rascati KL. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clin Ther. 1999;21:1443-1455, discussion 1427-1448.
49. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063.
50. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis-stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week (Abstract A1365). J Am Soc Nepbrol. 1999;10:270A.
51. Glaspy J, Jadeja J, Justice G, et al. Randomized, active-controlled, phase 1/2, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors (Abstract 1315). Eur J Cancer. 2001;37(Suppl 6):353.
52. Glaspy J, Colowick AB, Heatherington A. Novel erythropoiesis-stimulating protein (NESP) exhibits a prolonged serum half-life in oncology patients (Abstract 210). Proc Am Soc Clin Oncol. 2000;19:54a.
53. Kotasek D, Berg R, Poulsen E, Colowick A. Randomized, double-blind, placebo-controlled, phase I/II dose finding study of ARANESP administered once every three weeks in solid tumor patients. Blood. 2000;96(11 Suppl 1):294a.
54. Smith RE, Tchekmedyian NS, Chan D, et al. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer (Abstract 1320). Eur J Cancer. 2001;37(Suppl 6):355.
55. Smith RE, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001;84(Suppl 1):24-30.
56. Pirker R, Vansteenkiste J, Gateley J, et al. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis-stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer (Abstract 981). Eur J Cancer. 2001;37(Suppl 6):264.
57. Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost effectiveness, quality-adjusted life years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics. 1999;16(5 part 1):459-472.
58. Griggs JJ, Blumberg N. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia. Anticancer Drugs. 1998;9:925-932.
59. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer. 1998;83:2588-2596.
60. Audet A, Goodnough L. Practice strategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:403-406.
61. Smaniotto D, Luzi S, Morganti A. Prognostic significance of anemia and role of erythropoietin in radiation therapy. Tumori. 2000;86:17-23.